Repository logo
 
Publication

Unravelling the therapeutic effect of hnMSCs in an in vitro hepatic disease model of insulin resistance using hepatocyte-like cells and Kupffer cells

2024-10Doctoral thesis Restricted access
Simple item page
datacite.subject.fosCiências Médicas::Medicina Básicapt_PT
dc.contributor.advisorMiranda, Joana Paiva Gomes
dc.contributor.advisorRuas, Jorge Manuel Lira Gonçalves
dc.contributor.authorRodrigues, Joana S.
dc.date.accessioned2025-02-07T17:39:53Z
dc.date.available2025-02-07T17:39:53Z
dc.date.issued2024-10
dc.date.submitted2024-05
dc.description.abstractChronic liver diseases represent one of the leading causes of mortality worldwide. In particular, metabolic dysfunction-associated steatotic liver disease (MASLD) is the most common chronic liver disease in the Western world, fuelled by the increasing prevalence of obesity and diabetes. However, an effective therapy able to treat most patients is not yet available. Therefore, understanding disease development to identify potential drug targets is a pressing need. In this context, human stem cell-derived hepatocyte-like cells (HLCs) constitute a promising alternative to human primary hepatocytes and animal models for studying the mechanisms underlying liver disease and for testing the efficacy and safety of drugs or new therapies. However, the use of HLCs as a preclinical tool has been hampered by the immature phenotype obtained with current differentiation protocols. To address these problems, this thesis tested approaches to obtain a functional human-based stem cell-derived HLC model, able to mimic MASLD pathophysiological mechanisms and to evaluate therapeutic candidates. Accordingly, by modulating the concentration of differentiation-promoting compounds, such as glucose, insulin and dexamethasone, we could achieve a more physiologically relevant model with improved HLC biotransformation capacity and insulin responsiveness. Furthermore, HLC adaptation to a fit-for-purpose microfluidic culture system, constituting a microphysiological system, enhanced the degree of differentiation and drug metabolism capacity, demonstrated by the increased presence of hepatic-specific markers and production of diclofenac glucuronidation metabolites. Moreover, the establishment of insulin responsive HLCs set up the grounds for the development of a MASLD model. Thus, by exposing HLCs to oleic and palmitic acids, we could observe lipid accumulation, activation of gluconeogenesis, synthesis of lipotoxic species, such as ceramides and diacylglycerol, increased reactive oxygen species production and mitochondrial dysfunction along with induction of lipogenesis and gradual decrease in the antioxidant response. Additionally, considering that MASLD onset is correlated with liver zonation, in particular, perivenous (PV) hepatocytes, we explored the role of the hypoxia mimetic dimethyloxalylglycine (DMOG) in creating a PV-like HLC subpopulation. Of note, DMOG was more effective in inducing the expression of genes associated with PV-specific functions than exposing HLCs to 5% pO2. In addition, HLCs treated with DMOG presented signs of faster MASLD development, namely lower expression of genes involved in fatty acid oxidation and antioxidant response along with higher ceramide production levels. Thus, this platform not only presents itself as an alternative for the implementation of PV hepatocytes, but it could be further explored for the identification of biomarkers enabling earlier MASLD diagnosis. Lastly, the incorporation of the immune response in this hepatic model, by co-culturing HLCs and THP-1-derived macrophages, provided evidence on the therapeutic effect of mesenchymal stem cells’ secretome at the metabolic and immunomodulatory levels. Overall, this thesis demonstrated that recapitulating liver microenvironment is fundamental for unravelling the full potential of stem cell-derived HLCs for metabolic disease modelling, drug screening and drug metabolism assessment. Importantly, the therapeutic properties of the MSC secretome in MASLD setting should be evaluated in more detail.pt_PT
dc.description.provenanceSubmitted by Paula Guerreiro (passarinho@reitoria.ulisboa.pt) on 2025-02-04T15:45:14Z No. of bitstreams: 1 scnd990026354742261_td_Joana_Rodrigues.pdf: 8318481 bytes, checksum: c31843e1e710b6e7be35fe38125b3316 (MD5)en
dc.description.provenanceMade available in DSpace on 2025-02-07T17:39:53Z (GMT). No. of bitstreams: 1 scnd990026354742261_td_Joana_Rodrigues.pdf: 8318481 bytes, checksum: c31843e1e710b6e7be35fe38125b3316 (MD5) Previous issue date: 2024-10en
dc.identifier.tid101681178pt_PT
dc.identifier.urihttp://hdl.handle.net/10400.5/98231
dc.language.isoengpt_PT
dc.relationUnravelling the therapeutic effect of hnMSCs in an in vitro hepatic disease model of insulin resistance using hepatocytelike cells and Kupffer cells
dc.subjectCélulas tipo-hepatócitopt_PT
dc.subjectmodelos hepáticos in vitro humanospt_PT
dc.subjectDHEADMpt_PT
dc.subjectmetabolismo de xenobióticospt_PT
dc.subjectmodelos de doençapt_PT
dc.subjectcélulas estaminais mesenquimaispt_PT
dc.subjectsistemas microfisiológicospt_PT
dc.subjectHepatocyte-like cellspt_PT
dc.subjecthuman hepatic in vitro modelspt_PT
dc.subjectMASLDpt_PT
dc.subjectdrug metabolismpt_PT
dc.subjectdisease modellingpt_PT
dc.subjectmesenchymal stem cellspt_PT
dc.subjectmicrophysiological systemspt_PT
dc.titleUnravelling the therapeutic effect of hnMSCs in an in vitro hepatic disease model of insulin resistance using hepatocyte-like cells and Kupffer cellspt_PT
dc.typedoctoral thesis
dspace.entity.typePublication
oaire.awardTitleUnravelling the therapeutic effect of hnMSCs in an in vitro hepatic disease model of insulin resistance using hepatocytelike cells and Kupffer cells
oaire.awardURIinfo:eu-repo/grantAgreement/FCT/OE/SFRH%2FBD%2F144130%2F2019/PT
oaire.awardURIinfo:eu-repo/grantAgreement/FCT//COVID%2FBD%2F153540%2F2024/PT
oaire.fundingStreamOE
person.familyNameRodrigues
person.givenNameJoana
person.identifier666699
person.identifier.orcid0000-0002-1772-9813
project.funder.identifierhttp://doi.org/10.13039/501100001871
project.funder.identifierhttp://doi.org/10.13039/501100001871
project.funder.nameFundação para a Ciência e a Tecnologia
project.funder.nameFundação para a Ciência e a Tecnologia
rcaap.contributor.authoremailrepositorio@reitoria.ulisboa.ptpt_PT
rcaap.rightsrestrictedAccesspt_PT
rcaap.typedoctoralThesispt_PT
relation.isAuthorOfPublicationa636fbfb-0693-49b9-91b7-acbb45aefc69
relation.isAuthorOfPublication.latestForDiscoverya636fbfb-0693-49b9-91b7-acbb45aefc69
relation.isProjectOfPublicatione934a918-2198-401d-93eb-2acbaa071017
relation.isProjectOfPublication6f4c0a34-41df-4f96-a18f-624136134738
relation.isProjectOfPublication.latestForDiscoverye934a918-2198-401d-93eb-2acbaa071017
thesis.degree.nameTese de doutoramento, Farmácia (Toxicologia), Universidade de Lisboa, Faculdade de Farmácia, 2024pt_PT

Files

Original bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
scnd990026354742261_td_Joana_Rodrigues.pdf
Size:
7.93 MB
Format:
Adobe Portable Document Format
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.2 KB
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections